Efficacy of Inhibitory Control in Antisaccade Task and the Polymorphisms of DRD2 Dopamine Receptor Gene in Schizophrenic Patients
- Authors: Storozheva Z.I.1, Brodyansky V.M.1, Kirenskaya A.V.1, Tkachenko A.A.1, Kibitov A.O.1
- 
							Affiliations: 
							- Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
 
- Issue: Vol 44, No 6 (2018)
- Pages: 720-724
- Section: Short Communications
- URL: https://journals.rcsi.science/0362-1197/article/view/177859
- DOI: https://doi.org/10.1134/S0362119718050146
- ID: 177859
Cite item
Abstract
The purpose of this pilot study was to investigate the association of five polymorphic loci of the DRD2 gene (rs1799732, rs1800497, rs6277, rs6275, and rs2242592) with antisaccade task performance in male cohorts of schizophrenic patients (n = 33) and healthy subjects (n = 30). The antisaccade error rate was analyzed as related to prefrontal inhibitory control. In patients, the increased percent of errors was associated with minor alleles of polymorphisms rs6277 (C), rs6275 (T), and rs2242592 (G), which are supposedly related to the risk of schizophrenia. At the same time, it was found that a decreased error rate in healthy subjects is associated with the C/C variant of rs6277; no association was observed between polymorphisms rs6275 and rs2242592 and task performance.
About the authors
Z. I. Storozheva
Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
							Author for correspondence.
							Email: storozheva_zi@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow, 119034						
V. M. Brodyansky
Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
														Email: storozheva_zi@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow, 119034						
A. V. Kirenskaya
Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
														Email: storozheva_zi@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow, 119034						
A. A. Tkachenko
Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
														Email: storozheva_zi@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow, 119034						
A. O. Kibitov
Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
														Email: storozheva_zi@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow, 119034						
Supplementary files
 
				
			 
					 
						 
						 
						 
						 
				 
  
  
  
  
  Email this article
			Email this article  Open Access
		                                Open Access Access granted
						Access granted Subscription Access
		                                		                                        Subscription Access
		                                					